Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Opicapone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COMT known ✓ | P21964 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 5/20 | 0.37 |
| ▸ | NPC1 | O15118 | 4/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Opicapone SCHEMBL539065 | 1.00 | COMT (1.00) | COMTMAPTTTRRAB9ANPC1 | |
| Opicapone SCHEMBL31404127 | 1.00 | COMT (1.00) | COMTMAPTTTRRAB9ANPC1 | |
| Opicapone SCHEMBL29582646 | 1.00 | COMT (1.00) | COMTMAPTTTRRAB9ANPC1 | |
| SCHEMBL31681376 | 0.93 | COMT (0.87) | COMTMAPTTTRRAB9ANPC1 | |
| SCHEMBL1446970 | 0.93 | COMT (0.87) | COMTMAPTTTRRAB9ANPC1 | |
| SCHEMBL1447042 | 0.93 | COMT (0.87) | COMTMAPTTTRRAB9ANPC1 | |
| SCHEMBL20614242 | 0.92 | COMT (0.85) | COMTMAPTTTRRAB9ANPC1 | |
| SCHEMBL1447181 | 0.91 | COMT (0.84) | COMTMAPTTTRRAB9ANPC1 | |
| SCHEMBL15019301 | 0.89 | COMT (0.79) | COMTMAPTRAB9ANPC1HPGD | |
| SCHEMBL1446764 | 0.87 | COMT (0.78) | COMTMAPTTTRRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 669 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727649-A1 | PROCESS FOR PREPARING OPICAPONE | Medichem, S.A. (ES) | 2026-04-22 | — | — | EP | claimed |
| US-20260097039-A1 | METHODS FOR TREATING A FATTY LIVER DISEASE | MADRIGAL PHARMACEUTICALS INC (US) | 2026-04-09 | — | — | US | claimed |
| EP-4719374-A1 | TREATMENT REGIMENS FOR EARLY IDIOPATHIC PARKINSON'S DISEASE | Bial-Portela & CA, S.A. (PT) | 2026-04-08 | — | — | EP | claimed |
| US-20260091047-A1 | THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS | NATIVE CODE BIO LLC (US) | 2026-04-02 | — | — | US | claimed |
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| US-20260053782-A1 | TREATMENT REGIMENS FOR PARKINSON'S DISEASE | BIAL PORTELA & CA SA (PT) | 2026-02-26 | — | — | US | claimed |
| EP-4687683-A1 | CONTROL OF ULTRASOUND PROCEDURES BY MONITORING MICROBUBBLE RESPONSE | Insightec Ltd. (IL) | 2026-02-11 | — | — | EP | claimed |
| US-20260027178-A1 | Treatment Of Parkinson's Disease With SIM BHLH Transcription Factor 2 (SIM2) Agonists | REGENERON PHARMA (US) | 2026-01-29 | — | — | US | claimed |
| US-12533417-B2 | L-DOPA and/or DOPA decarboxylse inhibitors conjugated to sugar for the treatment of dopamine-responsive disorders | B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY (IL) | 2026-01-27 | — | — | US | claimed |
| US-20260000910-A1 | METHOD FOR TREATING PARKINSON'S DISEASE THROUGH PHOTOSTIMULATION, AND DEVICE USED IN SAID METHOD | TSUBOTA LAB INC (JP) | 2026-01-01 | — | — | US | claimed |
| WO-2022215051-A1 | METHODS OF TREATING NEURODEGENERATIVE DISORDERS WITH ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2022-10-13 | — | — | WO | claimed |
| US-20220323753-A1 | Methods of Treating Neurodegenerative Disorders with Alternating Electric Fields | NOVOCURE GMBH (CH) | 2022-10-13 | — | — | US | claimed |
| US-11413262-B2 | Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof | INTRANCE INTERNATIONAL AB (SE) | 2022-08-16 | — | — | US | claimed |
| WO-2022158992-A1 | TREATMENT OF PAIN ASSOCIATED WITH PARKINSON'S DISEASE WITH OPICAPONE IN COMBINATION WITH LEVODOPA | BIAL-PORTELA & CA., S.A. (PT) | 2022-07-28 | — | — | WO | claimed |
| WO-2022158991-A1 | TREATMENT OF PAIN ASSOCIATED WITH PARKINSON'S DISEASE WITH OPICAPONE IN COMBINATION WITH LEVODOPA | BIAL-PORTELA & CA., S.A. (PT) | 2022-07-28 | — | — | WO | claimed |
| WO-2022132923-A1 | TAU BINDING COMPOUNDS | VOYAGER THERAPEUTICS, INC. (US) | 2022-06-23 | — | — | WO | claimed |
| WO-2022131944-A1 | TREATMENT REGIMENS FOR EARLY IDIOPATHIC PARKINSON'S DISEASE | BIAL-PORTELA & CA., S.A. (PT) | 2022-06-23 | — | — | WO | claimed |
| WO-2022081033-A1 | OPICAPONE AND LEVODOPA FOR THE TREATMENT OF PARKINSON'S DISEASE | BIAL - PORTELA & Cª, S.A. (PT) | 2022-04-21 | — | — | WO | claimed |
| US-20220062279-A1 | TREATMENT OF MOVEMENT DISORDERS | CONTERA PHARMA A/S (DK) | 2022-03-03 | — | — | US | claimed |
| WO-2022025781-A1 | SOLID DISPERSION OF OPICAPONE | BIAL - PORTELA & Cª, S.A. (PT) | 2022-02-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097039-A1 | METHODS FOR TREATING A FATTY LIVER DISEASE | SLC10A1, CYP2C8, CYP4F8 | COMT 363/4885MAPT 4333/4885TTR 362/4885 |
| US-20260091047-A1 | THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS | HMBS, SNCA, PYGB | COMT 32/4885MAPT 278/4885TTR 3127/4885 |
| US-20260027178-A1 | Treatment Of Parkinson's Disease With SIM BHLH Transcription Factor 2 (SIM2) Agonists | PARK7, SNCA, LRRK2 | COMT 77/4885MAPT 204/4885TTR 3219/4885 |
| US-11413262-B2 | Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof | COMT, DDT, DDC | COMT 1/4885MAPT 1230/4885TTR 542/4885 |
| US-20260000910-A1 | METHOD FOR TREATING PARKINSON'S DISEASE THROUGH PHOTOSTIMULATION, AND DEVICE USED IN SAID METHOD | PARK7, SNCA, PMP22 | COMT 5/4885MAPT 532/4885TTR 209/4885 |
| US-20260053782-A1 | TREATMENT REGIMENS FOR PARKINSON'S DISEASE | COMT, DDC, DDT | COMT 1/4885MAPT 2657/4885TTR 2539/4885 |
| US-12533417-B2 | L-DOPA and/or DOPA decarboxylse inhibitors conjugated to sugar for the treatment of dopamine-responsive disorders | COMT, SLC6A3, DDT | COMT 1/4885MAPT 612/4885TTR 2971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.